Nemaura Pharma, the fast-growing UK biotechnology company, has won the Medilink East Midlands Innovation award for its unique transdermal range of drug delivery technologies, including the patented Micro-Patch™ product. This provides a highly consistent and effective method for delivering drugs such as vaccines through the skin using a low cost disposable device.
This latest recognition by life science sector experts comes just a year after Frost & Sullivan, the global growth strategy analysts, identified Nemaura’s drug delivery technologies as having the potential to revolutionise the way drugs are administered.
Dr Faz Chowdhury, Director, commented;
“We have been a member and a part of the Medilink East Midlands network for several years, and it’s an honour to have been selected as winners for the Innovation Award. We are excited for the future as we look to expand the range of vaccines and Biologics the Micro-Patch™ can deliver.”
Potter Clarkson LLP, sponsored the Innovation Award. Gareth Probert, Partner, commented;
“We offer our congratulations to Nemaura Pharma who, amid much competition, are very deserving winners of the Innovation Award. Innovation is essential for the growth and development of Life Sciences not only in the East Midlands, but globally and something we as a company champion.”
Nemaura are finalists for the nationwide Medilink UK National Awards, due to be announced in April 2018.
Nemaura Pharma’s ambitions for growth recently caught the attention of a UK national newspaper City and Finance reporter:
About Nemaura Pharma
Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.
The company employs multi-disciplinary teams of scientists and engineers working in cutting-edge innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.
The company has secured over £25m (over $30m) in licensing and development payments, and private investment. In addition, Nemaura has been awarded five highly competitive British Government grants, and the Frost & Sullivan 2016 Enabling Technology Leadership Award in Transdermal Drug Delivery.
Cautionary Statement Regarding Forward-Looking Statements.
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.